CLINICAL_TRIALS
trial_result
· 2019-10-22
Clinical Trial Update: A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma [Phase 2]
Summary
Phase 2 multi-center trial of entinostat (SNDX-275) in relapsed or refractory Hodgkin's lymphoma; study terminated with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Syndax Pharmaceuticals | Conditions: Hodgkin's Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2019-10-22